4.5 Review

A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management

期刊

BLOOD REVIEWS
卷 45, 期 -, 页码 -

出版社

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2020.100691

关键词

Epidemiology; Diagnosis; Pprognosis; Treatment; Myelofibrosis; Marrow fibrosis

向作者/读者索取更多资源

Treatment options for primary myelofibrosis are limited, but diagnosis can often be established through appropriate clinical history, examination, laboratory evaluation, and bone marrow biopsy. Recent studies have characterized prognostic factors and driver mutations better, leading to the development of treatment strategies based on risk factors and clinical phenotype.
Although understanding of the pathogenesis and molecular biology of primary myelofibrosis continues to improve, treatment options are limited, and several biological features remain unexplained. With an appropriate clinical history, exam, laboratory evaluation, and bone marrow biopsy, the diagnosis can often be established. Recent studies have better characterized prognostic factors and driver mutations in myelofibrosis, facilitated by use of next-generation sequencing. These advances have facilitated development of a management strategy that is based on both risk factors and clinical phenotype. For low-risk patients, treatment will depend on symptom severity. For patients with higher-risk disease, several treatments are available including JAK inhibitors, allogeneic hematopoietic stem cell transplant, and clinical trials using novel molecularly targeted therapies and rational drug combinations. In this review, we outline what is known about the disease pathogenesis, discuss an approach to reaching the diagnosis, review the prognosis of myelofibrosis, and detail current therapeutic strategies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据